{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/opioid-dependence/prescribing-information/writing-prescriptions-for-substitution-therapy/","result":{"pageContext":{"chapter":{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy","depth":2,"htmlHeader":"<!-- begin field f2ad9f17-5c9a-4773-9a4d-a76100b331d6 --><h2>How should I write a prescription for opioid substitution therapy?</h2><!-- end field f2ad9f17-5c9a-4773-9a4d-a76100b331d6 -->","summary":"","htmlStringContent":"<!-- begin item eed5e926-00ea-410b-809a-a76100b3322c --><!-- begin field 82c6fe6f-b594-4a50-ac0b-a76100b331d6 --><ul><li>In primary care, prescription forms for instalment dispensing are: FP10MDA in England, WP10MDA in Wales, and GP10 in Scotland. <ul><li>Schedule 2 controlled drugs (CDs) can be prescribed electronically via EPS. However, exceptions include: <ul><li>Oral liquid methadone — because currently, it isn’t possible for all dispensing systems to endorse electronic prescriptions for oral liquid methadone with a packaged dose endorsement, a paper FP10 prescription still needs to be generated.</li><li>Instalment prescribing — EPS cannot be used for prescribing in instalments.</li></ul></li></ul></li><li>Prescriptions must be indelible and can be computer generated, but must comply with the legal requirements (see <strong>Table 2</strong>).<ul><li>It must be signed by the prescriber with their usual handwritten signature (unless it's an electronic prescription).  </li><li>It needs to include the date on which it was issued (a computer-generated date or rubber stamp is acceptable).</li></ul></li><li>The prescription must specify an instruction to allow medication to be collected on days to cover when the pharmacy is closed. It is essential that the correct wording is used when writing the prescription — see <strong>Table 3 </strong>for specific Home Office approved wording which can be added to prescriptions to enable such advance supplies for unplanned pharmacy closures.<ul><li>If the prescription states the need to provide in advance for a Sunday, for example, the amount to supply in advance must be stated (as for any other planned instalment supply).</li><li>The pharmacist must only supply the prescription on the date on which it is due. If the person does not collect an instalment when it is due, that supply is no longer valid – it cannot be collected on another day.</li><li>Part instalments may be collected provided the approved Home Office wording is included on the prescription — if the person is required to collect more than one day’s supply at a time and misses the specified day for collection, they will be able to collect the remaining balance of the instalment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">NHS Digital, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">PSNC, 2019</a>]</p><p><strong>Table 2.</strong> Writing prescriptions for substitute prescribing of methadone and buprenorphine.</p><table><thead><tr><th scope=\"col\">Issue</th><th scope=\"col\">Comments</th></tr></thead><tbody><tr><td>Legal requirements for writing CD prescriptions</td><td><p>All prescriptions must include the following: </p><ul><li>The patient's full name, address and, where appropriate, age.</li><li>The form and strength of the preparation. </li><li>The dose to be taken. <ul><li>A dose of 'as directed' or 'when required' is not acceptable, but 'one to be taken as directed/when required' is acceptable.</li></ul></li><li>The total quantity of the preparation or the number of dose units in both words and figures. </li><li>The signature of the prescriber who has written the prescription. </li><li>The date of signing by the prescriber who has written the prescription.</li></ul></td></tr><tr><td>Other practical points when writing instalment prescriptions</td><td><ul><li>Instalments can only be authorized for up to 14 days (in England and Wales). </li><li>Prescriptions must:<ul><li>State the intended date on which the first instalment should start. </li><li>Specify the dispensing instructions (for example, daily dispensing) and the amount to be dispensed.</li><li>Specify 'supervised consumption' if a local scheme is in place. </li></ul></li><li>If extra quantities need to be prescribed on any day because the pharmacy is closed on a Sunday or Bank Holiday, specify the actual days and quantities to be supplied for those days.<ul><li>Once specified, the prescription cannot be dispensed on alternative days. </li></ul></li><li>Limit supply on a single prescription to 28 days. </li><li>Issue the prescription directly to the person who uses drugs where possible.  </li><li>Collection of methadone or buprenorphine should usually be undertaken by the person the prescription is for.<ul><li>If a third-party is collecting the prescription, the pharmacy will require a covering letter from the person the prescription is for, and the prescriber should add this instruction to the prescription. </li></ul></li><li>Other prescription items cannot be written on the same form. </li></ul></td></tr><tr><td colspan=\"2\"><strong>Source:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>]</td></tr></tbody></table><p><br><strong>Table 3.</strong> Home Office approved wording requirements when writing instalment prescriptions</p><table><thead><tr><th scope=\"col\">Situation</th><th scope=\"col\">Examples of what to write on the prescription</th></tr></thead><tbody><tr><td><p>Where consumption is required to be supervised </p></td><td><p>Supervise consumption on collection days</p><p>(The frequency of supervised consumption may also be added if necessary)</p></td></tr><tr><td>Buprenorphine are required to be crushed<br>(local policy or agreement must be in place). </td><td>Please crush<p>Note: Buprenorphine-naloxone as a combination product should not be crushed</p></td></tr><tr><td><p>To cover pickups due on bank holidays, public holidays or other irregular or emergency pharmacy closures </p></td><td><p>Please dispense instalments due on pharmacy closed days on a prior suitable day</p><p>For the regular closure of a pharmacy such as on Sundays, the prescriber’s intention should be made clear by stating the total amount of the advance instalment supply.</p></td></tr><tr><td><p>To cover pick up to be less frequently than daily </p><p>State days or dates for collection and total amount of the individual instalment, or specify amounts to be dispensed for individual dates</p></td><td><p>For 60ml daily, this would be:</p><p>Collect on Mondays, Wednesdays and Fridays. 120ml on Mondays and Wednesdays and 180ml on Fridays,<br><br>or </p><p>22.07.19 120ml<br>24.07.19 120ml<br>26.07.19 180ml</p></td></tr><tr><td><p>To allow collection of part instalments following a missed pick up </p></td><td><p>If an instalment’s collection day has been missed, please still dispense the amount due for any remaining day(s) of that instalment</p></td></tr><tr><td><p>To ensure the person is not supplied with their dose without consultation with prescribing service or prescriber if they have missed collection for three or more days </p></td><td><p>Consult the prescriber if three or more consecutive days of a prescription have been missed</p><p>(This does not invalidate the prescription but the prescriber should be consulted for advice. The service may wish to assess the person before agreeing whether the prescription can continue)</p></td></tr><tr><td>If you want the pharmacy to supply methadone in pre-measured amounts for days of multiple collection. </td><td><p>Dispense daily doses in separate containers</p></td></tr><tr><td colspan=\"2\"><strong>Source:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/opioid-dependence/references/\">DH, 2017</a>]</td></tr></tbody></table><!-- end field 82c6fe6f-b594-4a50-ac0b-a76100b331d6 --><!-- end item eed5e926-00ea-410b-809a-a76100b3322c -->","topic":{"id":"ef534296-f504-5d3e-9b47-3c0f08322658","topicId":"1acd30d9-6aea-492b-a570-5fbeb05d49f5","topicName":"Opioid dependence","slug":"opioid-dependence","lastRevised":"Last revised in October 2020","chapters":[{"id":"7b9e0e1a-3aea-5219-a001-dfd22a786292","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0179729-bb50-55a3-a1dc-ca3cbd473972","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e63e1346-068d-56e6-891b-85878800d361","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"37edcefe-2b9f-5ab8-a584-be9e268559ac","slug":"changes","fullItemName":"Changes"},{"id":"b53b49f5-e58d-5325-8fee-7f9fdc057646","slug":"update","fullItemName":"Update"}]},{"id":"242f440f-b9b5-51a4-9d43-3492e963e9af","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5766349b-04fe-548c-9de5-0ff28c7803b9","slug":"goals","fullItemName":"Goals"},{"id":"2ed8ffe3-15a2-5e49-b2ad-033e1a4b5f22","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"419add6c-5149-5bbf-9be1-8854fefbccc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01b28023-8c52-53e9-a23d-43bb73f67990","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e459f916-c763-56aa-9a4e-a3e6ef261b0f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a96bc65-6eb3-5a1c-99c3-2530b6d352f4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b1fa8640-11da-554d-9d7a-12696b906136","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"28447573-cc1d-50d6-bea5-720f6d22e335","slug":"definition","fullItemName":"Definition"},{"id":"d7f47150-a2c5-57f9-88aa-5353f86fc58a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e594be8-c4df-5032-ad75-87ab56cb2c7e","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7da5320-e6b9-59fc-8e5a-558ea4c298d9","slug":"complications","fullItemName":"Complications"}]},{"id":"e747d7e1-25ca-5f67-9d22-349d2b18eddd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ee9cab5c-4665-56a2-9005-028143cc8f59","slug":"suspecting-opioid-dependency","fullItemName":"Suspecting opioid dependency"},{"id":"20c15a53-634f-5cb4-a88a-7cb5115d810b","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"f37505e6-dc82-5755-b700-7d1966f8c252","fullItemName":"Management","slug":"management","subChapters":[{"id":"75fe82a9-9ba2-541a-80be-cd0cf879bca3","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"d05968e4-f2be-5378-b462-0b129f5dc5e6","slug":"management","fullItemName":"Scenario: Management"},{"id":"00d16467-be2b-538d-8a7c-4d4045cabd6e","slug":"managing-special-circumstances","fullItemName":"Scenario: Managing special circumstances"}]},{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ccbe88d0-314a-57fa-a61a-8a83bbfc9baf","slug":"writing-prescriptions-for-substitution-therapy","fullItemName":"Writing prescriptions for substitution therapy"},{"id":"5c859eeb-d8fd-50f5-8b18-e1a6a71ac111","slug":"methadone","fullItemName":"Methadone"},{"id":"3021db45-0a93-5ca8-a386-8d3e71abad63","slug":"buprenorphine","fullItemName":"Buprenorphine"}]},{"id":"9547692f-53b7-5f09-944d-6a4a6229dead","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0eafd778-db7f-578e-905f-1365ee1290a1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d80b232-8932-503b-8765-30b929f15180","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"796c8942-47b7-56b5-a88a-cc0f133f5f3e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cfb530c5-aa05-5f4c-9e26-43caae839601","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"955b9fba-573b-57a0-b099-cf3356d6e837","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f05fac2-c160-5e48-b55d-3898cce03ec0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0ead7d6b-f923-5852-bb7c-50aa97b9b2ff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cf2cc09-9ca4-58a8-91c7-d64c38924b5a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}